The European Commission's DG Research and Innovation considers DEEP project as an excellent example of fruitful project.

Children born with thalassaemia cannot create normal haemoglobin, which is needed to produce healthy red blood cells. Regular blood transfusions are the only treatment available, but iron overload is inevitable. Since iron accumulation can cause potentially fatal multi-organ dysfunction, transfusion therapy is coupled with iron chelation. Deferiprone (DFP) – authorised in Europe in 1999 – is considered very effective, but it has remained second in line and in fact discouraged for treating children under the age of six due to a scarcity of studies involving paediatric patients.

DEEP Consortium is working on the integration of the existing information on deferiprone use in paediatric patients, and providing a valid support to the use of the drug in this class of age.

The project is led by Consorzio per le Valutazioni Biologiche e Farmacologiche and founded by FP7. Fondazione per la Ricerca Farmacologica Gianni Benzi is involved in the management of regulatory and ethical issues, study protocols and ethical issues, market evaluation, development of a budget impact model and performance of pharmacoeconomic evaluation.

The full article is available [here].

Pin It on Pinterest

Share This